These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2007324)

  • 1. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.
    Meyers FJ; Paradise C; Scudder SA; Goodman G; Konrad M
    Clin Pharmacol Ther; 1991 Mar; 49(3):307-13. PubMed ID: 2007324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
    Katre NV
    J Immunol; 1990 Jan; 144(1):209-13. PubMed ID: 2295792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects.
    Sarna G; Collins J; Figlin R; Robertson P; Altrock B; Abels R
    J Biol Response Mod; 1990 Feb; 9(1):81-6. PubMed ID: 2319262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion.
    Edwards RP; Gooding W; Lembersky BC; Colonello K; Hammond R; Paradise C; Kowal CD; Kunschner AJ; Baldisseri M; Kirkwood JM; Herberman RB
    J Clin Oncol; 1997 Nov; 15(11):3399-407. PubMed ID: 9363872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.
    Zimmerman RJ; Aukerman SL; Katre NV; Winkelhake JL; Young JD
    Cancer Res; 1989 Dec; 49(23):6521-8. PubMed ID: 2819708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.
    Libutti SK; Paciotti GF; Byrnes AA; Alexander HR; Gannon WE; Walker M; Seidel GD; Yuldasheva N; Tamarkin L
    Clin Cancer Res; 2010 Dec; 16(24):6139-49. PubMed ID: 20876255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of route and formulation on clinical pharmacokinetics of interleukin-2.
    Anderson PM; Sorenson MA
    Clin Pharmacokinet; 1994 Jul; 27(1):19-31. PubMed ID: 7955769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and preclinical evaluation of recombinant PEG-IL-2 in human.
    Menzel T; Schomburg A; Körfer A; Hadam M; Meffert M; Dallmann I; Casper S; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Biother; 1993; 8(3):199-212. PubMed ID: 7804360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of PEG recombinant human interleukin-6 in rats].
    He XL; Yang G; Yin HL; Zhang XM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):149-52. PubMed ID: 19292067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
    Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
    J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.
    Nieforth KA; Nadeau R; Patel IH; Mould D
    Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
    George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors.
    Norris RE; Shusterman S; Gore L; Muscal JA; Macy ME; Fox E; Berkowitz N; Buchbinder A; Bagatell R
    Pediatr Blood Cancer; 2014 Oct; 61(10):1792-7. PubMed ID: 24962521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
    Clark JI; Mehrabi J; Sosman JA; Logan TF; Margolin KA; Dutcher JP; Urba WJ; Ernstoff MS; McDermott DF; Lau AM; Atkins MB
    J Immunother; 2007; 30(8):839-46. PubMed ID: 18049336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.